🔗 Share this article

As the US undertakes historic revisions to its vaccination recommendations, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by casting doubt on coronavirus shots in the pandemic and has zeroed in on possible deaths after Covid immunization in her brief tenure at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Schedule

Health officials were set to announce radical changes to the pediatric vaccine schedule earlier this month, bringing the US with the Danish vaccine program, according to reports – a significant shift that would put the US out of step with many the world with insufficient data for improved outcomes. The planned update has been pushed back until the new year.

Rather than Vinay Prasad, Høeg is set to address the audience at the event. She was recently named interim head of the FDA’s CDER, the fifth person to head the division this year.

A New Direction at the Agency

Høeg's temporary position might represent a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific pediatric vaccine recommendations in the US so as to align more like Denmark's approach, a society with universal health coverage and a population roughly the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccines – usually the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Qualifications

Dr. Høeg has no apparent experience in medication creation, oversight or leadership, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in managing a large organization. She lacks background in industry regulation.”

Past directors of the center would “grasp laws and regulations and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that prior appointees who headed the center have had.”

The drug center has an immense portfolio at the FDA, she pointed out.

“Many people just pays attention on the innovative therapies, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and more, and each of these need to be managed,” Dr. Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial leadership element to the position, which manages in excess of 5,000 staff members. “It’s a massive administrative position, if you execute it properly,” Woodcock said.

Official Statement and Controversial Programs

In response to concerns about Dr. Høeg's fitness for the role and whether this assignment represents more teamwork among regulatory chiefs on immunizations, a spokesperson said that the “inquiries rely on inaccurate presumptions”.

“This background aligns with the duties of her position,” the official explained, pointing to the period Høeg spent guiding the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's controversial priority voucher program, a disputed rapid medication authorization process that apparently troubled her predecessors. “By what process are these drugs being chosen for this fast-track system? Who makes the calls?” Dr. Howard said. “There’s a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards less stringent regulations of all drugs, with the exception of vaccines.”

Documented Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if concerning, past, Howard observe. She published a analysis using non-validated crowd-sourced reports to assess the incidence of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the new government featured altering regulations for new vaccines and ending “unnecessary” vaccines, she stated following the vote on a podcast. At the FDA, Høeg has allegedly proposed excluding teenage boys from receiving COVID-19 vaccinations.

“She is an thorough dogmatist who starts off with her conclusions and tailors the evidence to retrofit the science in a extremely disingenuous, untruthful way,” Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|